MaxCyte Plans $151.8M Akron Bio Deal for Cell Therapy

Confidential manufacturing records sit behind the cytokines and media Akron Bio sells. Those records let a therapy developer reference information about a supplier's materials inside its own regulatory submission. For a buyer of the supplier, that existing place in the customer's process is a substantial part of the attraction.

MaxCyte is seeking to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management for $151.8M, under an agreement announced November 10, 2026. The proposed combination would connect MaxCyte's cell-engineering technology with more of the ingredients used around it, giving the Rockville, Maryland company a broader role in cell-therapy manufacturing. Closing is expected before year-end, subject to customary conditions.

What MaxCyte is buying alongside the materials

Akron Bio has supplied ancillary materials for cell and gene therapies since 2006. Its product and manufacturing portfolio includes cytokines, plasma-derived materials, custom proteins, media and buffers. These are practical inputs for the teams trying to turn a promising treatment into a process they can repeat reliably.

The less visible work appears in Akron's regulatory support. Drug master files contain confidential information about manufacturing, processing, packaging, storage and material characteristics, allowing regulators to review supporting information for a customer's submission. Akron also offers regulatory support files, audit access under quality agreements and notifications before product changes.

That gives the acquisition a commercial logic beyond adding more items to a catalog. A customer buying a material also depends on the documentation and technical cooperation that accompany it. The relationship can reach into process development and regulatory preparation, making continuity part of what the supplier has to deliver every time.

MaxCyte has already expanded beyond its original engineering tools. Its January 2025 acquisition of SeQure Dx added gene-editing assessment services, including work on unintended editing effects. Akron would extend the business in another direction, into the materials used across manufacturing. Together, those moves show MaxCyte seeking more ways to serve a developer as the developer's program advances.

How the $151.8M transaction is structured

The purchase agreement separates the price into three components. MaxCyte would pay $105M in cash at closing, subject to customary adjustments, issue 20,639,733 common shares, and make $20M in guaranteed deferred cash payments. The shares were valued at approximately $26.8M using MaxCyte's November 9 closing price; their market value can subsequently change.

The deferred payments are $10M each on the first business day of January 2028 and January 2029. They are guaranteed payments rather than a performance earnout. That distinction matters when interpreting how much of the stated consideration depends on the acquired business hitting future targets.

The SEC filing describing the agreement also identifies closing conditions, including expiration or termination of any applicable Hart-Scott-Rodino waiting period and approval to list the stock consideration on Nasdaq. The transaction does not require MaxCyte shareholder approval and has no financing condition. The disclosed six-month lockup on the shares would keep the sellers exposed to MaxCyte after closing.

For Arcline, accepting stock ties part of the exit's value to the buyer's subsequent performance. For MaxCyte, that structure spreads the consideration across cash, equity and time. The economic relationship continues after the transfer of ownership, even as the operating responsibility shifts toward the combined business.

The revenue opportunity carries an operating obligation

In its transaction presentation, MaxCyte forecasts approximately $28M in Akron revenue for 2026 and $7M-$8M in EBITDA, a non-GAAP measure. The presentation describes a business with meaningful commercial-stage exposure: roughly 40%-45% of Akron revenue comes from commercial-stage customers, according to management's disclosed mix. These figures describe the acquisition thesis and expected performance, rather than completed combined-company results.

MaxCyte's third-quarter results provide the buyer's starting point. The company reported approximately $10.2M in quarterly revenue and raised standalone full-year 2026 revenue guidance to at least $34.5M. That scale helps explain management's expectation that acquiring Akron would nearly double its revenue base.

The acquisition announcement says the combined portfolio would support 5 commercially approved therapies and more than 100 clinical programs. MaxCyte also reports limited customer overlap, despite similar buying contacts and end markets. That creates a plausible route for cross-selling: an existing customer conversation could become relevant to another part of the manufacturing process.

The people carrying those conversations matter. Maher Masoud, MaxCyte's President and CEO, is pursuing the broader supplier role; Akron's leadership team includes founder and Executive Chair Claudia Zylberberg, COO Ezequiel Zylberberg and President and CCO David Smith. Their company's value includes knowing how to support work that customers have already put into motion.

Financing the combination while preserving customer continuity

A separate MidCap Financial credit facility offers up to $75M, split between a $55M term loan and a $20M revolver. MaxCyte expects to draw $20M of the term loan and $2M of the revolver at closing. The facility's maximum capacity should be kept separate from cash drawn and from the acquisition consideration.

Management expects approximately $40M-$45M in cash at closing and combined annual cash burn below $10M in 2027. Those projections underpin its stated plan to reach profitability without using the full facility. They still depend on the transaction closing and the combined business performing as expected.

For therapy developers, the immediate concern is how the supplier relationship carries through. In its own announcement, Akron emphasizes the consistent execution and supply reliability that its partners depend on. MaxCyte expects Akron to keep its brand, with the leadership team and employees contributing to the combination. Keeping that continuity intact gives MaxCyte a foundation for discussing additional products without making an established customer relearn who is responsible for the materials already in use.

The acquisition would put MaxCyte in more of the working day of a cell-therapy manufacturer. A conversation that begins with engineering cells could continue into the media, reagents and supporting records surrounding the next batch. Each additional place in that process brings another reason for the customer to call, and another obligation for the supplier answering.